RPG Life Sciences to Acquire Raghava's API Business for Rs 135 Crores
RPG Life Sciences Ltd · Others (Uncategorized) · 03 Sept 2026, 3:48 am
RPG Life Sciences to Acquire Raghava's API Business for Rs 135 Crores RPG Life Sciences’ subsidiary, RPG Active Pharma, will acquire Raghava Life Sciences' API and intermediates business via slump sale for a cash consideration up to Rs 135 crores. The acquired business generated unaudited FY26 revenues of Rs 19 crores and includes manufacturing and R&D facilities, alongside 29 API molecules (22 commercialized). Expected to close within 30 days from 2nd Sep'26, the deal strategically expands RPG's API operations. Raghava's CRO and CRAMS divisions are explicitly excluded from this transaction.
Original exchange filing (PDF)
More announcements from RPG Life Sciences Ltd
- Earning call Transcript · 05 Nov 2026
- Audio Recording of Q2FY27 Results Earnings Call held on October 30, 2026 · 31 Oct 2026
- Investor Presentation · 30 Oct 2026
- Amendment to Policy on Related Party Transactions · 30 Oct 2026
- Press Release · 30 Oct 2026
- Outcome of Board Meeting held on October 29, 2026. · 30 Oct 2026
- Financial Result for the quarter ended September 30, 2026 · 30 Oct 2026
- Outcome of Board Meeting · 30 Oct 2026
